The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Prophylactic Human Vaccine-Global Market Insights and Sales Trends 2025
Synopsis
Vaccination in the body of a healthy person causes the person to produce antibodies and obtain specific immunity in the absence of disease. For example, BCG vaccination, smallpox vaccination and so on.
The global Prophylactic Human Vaccine market size is expected to reach US$ 340.7 million by 2029, growing at a CAGR of 8.4% from 2023 to 2029. The market is mainly driven by the significant applications of Prophylactic Human Vaccine in various end use industries. The expanding demands from the Hospital, Scientific Research and Others,, are propelling Prophylactic Human Vaccine market. Inactivated Vaccine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Attenuated Vaccine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Prophylactic Human Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Prophylactic Human Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Prophylactic Human Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Prophylactic Human Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Prophylactic Human Vaccine covered in this report include GSK, Biovac, McKesson Medical, Merck, Merial, Zoetis and Sanofi, etc.
The global Prophylactic Human Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
Biovac
McKesson Medical
Merck
Merial
Zoetis
Sanofi
Global Prophylactic Human Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Prophylactic Human Vaccine market, Segment by Type:
Inactivated Vaccine
Attenuated Vaccine
Others
Global Prophylactic Human Vaccine market, by Application
Hospital
Scientific Research
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Prophylactic Human Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Prophylactic Human Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Vaccination in the body of a healthy person causes the person to produce antibodies and obtain specific immunity in the absence of disease. For example, BCG vaccination, smallpox vaccination and so on.
The global Prophylactic Human Vaccine market size is expected to reach US$ 340.7 million by 2029, growing at a CAGR of 8.4% from 2023 to 2029. The market is mainly driven by the significant applications of Prophylactic Human Vaccine in various end use industries. The expanding demands from the Hospital, Scientific Research and Others,, are propelling Prophylactic Human Vaccine market. Inactivated Vaccine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Attenuated Vaccine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Prophylactic Human Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Prophylactic Human Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Prophylactic Human Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Prophylactic Human Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Prophylactic Human Vaccine covered in this report include GSK, Biovac, McKesson Medical, Merck, Merial, Zoetis and Sanofi, etc.
The global Prophylactic Human Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
Biovac
McKesson Medical
Merck
Merial
Zoetis
Sanofi
Global Prophylactic Human Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Prophylactic Human Vaccine market, Segment by Type:
Inactivated Vaccine
Attenuated Vaccine
Others
Global Prophylactic Human Vaccine market, by Application
Hospital
Scientific Research
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Prophylactic Human Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Prophylactic Human Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Prophylactic Human Vaccine Market Overview
1.1 Prophylactic Human Vaccine Product Overview
1.2 Prophylactic Human Vaccine Market Segment by Type
1.2.1 Inactivated Vaccine
1.2.2 Attenuated Vaccine
1.2.3 Others
1.3 Global Prophylactic Human Vaccine Market Size by Type
1.3.1 Global Prophylactic Human Vaccine Market Size Overview by Type (2018-2029)
1.3.2 Global Prophylactic Human Vaccine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Prophylactic Human Vaccine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Prophylactic Human Vaccine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Prophylactic Human Vaccine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Prophylactic Human Vaccine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Prophylactic Human Vaccine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Prophylactic Human Vaccine Sales Breakdown by Type (2018-2023)
2 Global Prophylactic Human Vaccine Market Competition by Company
2.1 Global Top Players by Prophylactic Human Vaccine Sales (2018-2023)
2.2 Global Top Players by Prophylactic Human Vaccine Revenue (2018-2023)
2.3 Global Top Players by Prophylactic Human Vaccine Price (2018-2023)
2.4 Global Top Manufacturers Prophylactic Human Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Prophylactic Human Vaccine Market Competitive Situation and Trends
2.5.1 Prophylactic Human Vaccine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Prophylactic Human Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Prophylactic Human Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Prophylactic Human Vaccine Market
2.8 Key Manufacturers Prophylactic Human Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Prophylactic Human Vaccine Status and Outlook by Region
3.1 Global Prophylactic Human Vaccine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Prophylactic Human Vaccine Historic Market Size by Region
3.2.1 Global Prophylactic Human Vaccine Sales in Volume by Region (2018-2023)
3.2.2 Global Prophylactic Human Vaccine Sales in Value by Region (2018-2023)
3.2.3 Global Prophylactic Human Vaccine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Prophylactic Human Vaccine Forecasted Market Size by Region
3.3.1 Global Prophylactic Human Vaccine Sales in Volume by Region (2024-2029)
3.3.2 Global Prophylactic Human Vaccine Sales in Value by Region (2024-2029)
3.3.3 Global Prophylactic Human Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Prophylactic Human Vaccine by Application
4.1 Prophylactic Human Vaccine Market Segment by Application
4.1.1 Hospital
4.1.2 Scientific Research
4.1.3 Others
4.2 Global Prophylactic Human Vaccine Market Size by Application
4.2.1 Global Prophylactic Human Vaccine Market Size Overview by Application (2018-2029)
4.2.2 Global Prophylactic Human Vaccine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Prophylactic Human Vaccine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Prophylactic Human Vaccine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Prophylactic Human Vaccine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Prophylactic Human Vaccine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Prophylactic Human Vaccine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Prophylactic Human Vaccine Sales Breakdown by Application (2018-2023)
5 North America Prophylactic Human Vaccine by Country
5.1 North America Prophylactic Human Vaccine Historic Market Size by Country
5.1.1 North America Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Prophylactic Human Vaccine Sales in Volume by Country (2018-2023)
5.1.3 North America Prophylactic Human Vaccine Sales in Value by Country (2018-2023)
5.2 North America Prophylactic Human Vaccine Forecasted Market Size by Country
5.2.1 North America Prophylactic Human Vaccine Sales in Volume by Country (2024-2029)
5.2.2 North America Prophylactic Human Vaccine Sales in Value by Country (2024-2029)
6 Europe Prophylactic Human Vaccine by Country
6.1 Europe Prophylactic Human Vaccine Historic Market Size by Country
6.1.1 Europe Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Prophylactic Human Vaccine Sales in Volume by Country (2018-2023)
6.1.3 Europe Prophylactic Human Vaccine Sales in Value by Country (2018-2023)
6.2 Europe Prophylactic Human Vaccine Forecasted Market Size by Country
6.2.1 Europe Prophylactic Human Vaccine Sales in Volume by Country (2024-2029)
6.2.2 Europe Prophylactic Human Vaccine Sales in Value by Country (2024-2029)
7 Asia-Pacific Prophylactic Human Vaccine by Region
7.1 Asia-Pacific Prophylactic Human Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Prophylactic Human Vaccine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Prophylactic Human Vaccine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Prophylactic Human Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Prophylactic Human Vaccine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Prophylactic Human Vaccine Sales in Value by Region (2024-2029)
8 Latin America Prophylactic Human Vaccine by Country
8.1 Latin America Prophylactic Human Vaccine Historic Market Size by Country
8.1.1 Latin America Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Prophylactic Human Vaccine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Prophylactic Human Vaccine Sales in Value by Country (2018-2023)
8.2 Latin America Prophylactic Human Vaccine Forecasted Market Size by Country
8.2.1 Latin America Prophylactic Human Vaccine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Prophylactic Human Vaccine Sales in Value by Country (2024-2029)
9 Middle East and Africa Prophylactic Human Vaccine by Country
9.1 Middle East and Africa Prophylactic Human Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Prophylactic Human Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Prophylactic Human Vaccine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Prophylactic Human Vaccine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Prophylactic Human Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Prophylactic Human Vaccine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Prophylactic Human Vaccine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 GSK
10.1.1 GSK Company Information
10.1.2 GSK Introduction and Business Overview
10.1.3 GSK Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 GSK Prophylactic Human Vaccine Products Offered
10.1.5 GSK Recent Development
10.2 Biovac
10.2.1 Biovac Company Information
10.2.2 Biovac Introduction and Business Overview
10.2.3 Biovac Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Biovac Prophylactic Human Vaccine Products Offered
10.2.5 Biovac Recent Development
10.3 McKesson Medical
10.3.1 McKesson Medical Company Information
10.3.2 McKesson Medical Introduction and Business Overview
10.3.3 McKesson Medical Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 McKesson Medical Prophylactic Human Vaccine Products Offered
10.3.5 McKesson Medical Recent Development
10.4 Merck
10.4.1 Merck Company Information
10.4.2 Merck Introduction and Business Overview
10.4.3 Merck Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Merck Prophylactic Human Vaccine Products Offered
10.4.5 Merck Recent Development
10.5 Merial
10.5.1 Merial Company Information
10.5.2 Merial Introduction and Business Overview
10.5.3 Merial Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Merial Prophylactic Human Vaccine Products Offered
10.5.5 Merial Recent Development
10.6 Zoetis
10.6.1 Zoetis Company Information
10.6.2 Zoetis Introduction and Business Overview
10.6.3 Zoetis Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Zoetis Prophylactic Human Vaccine Products Offered
10.6.5 Zoetis Recent Development
10.7 Sanofi
10.7.1 Sanofi Company Information
10.7.2 Sanofi Introduction and Business Overview
10.7.3 Sanofi Prophylactic Human Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Sanofi Prophylactic Human Vaccine Products Offered
10.7.5 Sanofi Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Prophylactic Human Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Prophylactic Human Vaccine Industrial Chain Analysis
11.4 Prophylactic Human Vaccine Market Dynamics
11.4.1 Prophylactic Human Vaccine Industry Trends
11.4.2 Prophylactic Human Vaccine Market Drivers
11.4.3 Prophylactic Human Vaccine Market Challenges
11.4.4 Prophylactic Human Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Prophylactic Human Vaccine Distributors
12.3 Prophylactic Human Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
